Jazz Says Rival Lung Cancer Drug Will Be A 2027 Headwind For Zepzelca, Even As It Raises 2026 Outlook
Jazz lifted its 2026 revenue range to $4.775 billion to $4.85 billion while flagging a competitor to its small cell lung cancer drug.
Jazz Pharmaceuticals, which makes medicines for sleep disorders, epilepsy and cancer, expects a rival small cell lung cancer drug to hurt sales of its Zepzelca in 2027, Chief Commercial Officer Sam Pearce told analysts on the company's third-quarter earnings call Monday. The company still raised its 2026 revenue guidance to a $4.775 billion to $4.85 billion range.
A competitor with strong data
Answering a Piper Sandler analyst, Pearce said strong competitor data in first-line maintenance treatment of extensive-stage small cell lung cancer, presented at the ESMO Congress in October, is notable. The rival drug is not yet approved or reimbursed in that setting, she said, but once it is, she expects it "will represent a competitive headwind in 2027."
She said the segment accounts for about 30 to 40% of what she called "our total revenue," a phrase that leaves unclear whether she meant Zepzelca or all of Jazz. She also said the second-line monotherapy indication was removed from the Zepzelca label at the end of September, in alignment with the FDA, and that the removal does not affect the first-line maintenance approval.
Pearce said no impact is anticipated on the raised 2026 guidance. She called Zepzelca an established, practical and familiar standard for community oncologists who value convenient administration and proven survival benefit. More options are good news for patients, she said, and "both treatments have a place."
Zepzelca's quarter
Zepzelca net product sales rose 32% to $104 million in the third quarter, which Pearce attributed to strong adoption of its combination with atezolizumab in first-line maintenance. Jazz's oncology revenue grew 35% year over year.
Chief Financial Officer Phil Johnson said Jazz had 14 shipping weeks for U.S. oncology products in last year's third quarter against 13 this year, a nine-percentage-point headwind to U.S. oncology growth.
Raised outlook and a retiring commercial chief
Total third-quarter revenue was a record $1.24 billion, up 10% from a year earlier, CEO Renee Gala said. Johnson said the new guidance range implies nearly 13% growth over 2025 at the midpoint, and that it is the second straight quarter the low end of the range sits above the high end of the prior one. A little over half the increase came from rare sleep, he said, with high-sodium generics of Xywav having little impact.
Gala said Pearce will retire and will stay with Jazz until her successor is appointed to support the transition.
Pearce said Jazz is focused on driving first-line maintenance adoption ahead of the competitor's anticipated 2027 launch.
Sources
- Jazz Pharmaceuticals Non-GAAP EPS of -$3.88 misses by $1.50, revenue of $1.24B beats by $30M (JAZZ:NASDAQ) | Seeking Alpha — seekingalpha.com
- Jazz's Actio buyout gives rise to Setara with $90M series A — fiercebiotech.com
- Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results — prnewswire.com
- Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026 — prnewswire.com